Lipid CA2d
Version 1.aaec862d · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Lipid CA2d |
| Synonyms | Not available |
| SMILES | Not available |
| Formula | Not available |
| M.Wt | Not available |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Wang S, Zhong Y, Wang C, Tian M, Bennett JL, Bliss-Moreau E, Xue Y, Yu C, Hou X, Zheng YY, Li H, Liu Z, Cao D, Kang DD, Deng B, Dong Y. Overcoming the blood-brain barrier using central nervous system-accessing lipid nanoparticles for enhanced mRNA therapeutics. Proc Natl Acad Sci U S A. 2026 Aug 18;123(33):e2538147123. doi: 10.1073/pnas.2538147123. Epub 2026 Aug 14. PMID: 42599788. |
CA2d is an ionizable lipid developed for systemic mRNA delivery to the central nervous system. Its architecture combines an MK-0752-derived CNS-accessing moiety, a short three-carbon diamine spacer, a tertiary ionizable amine, and two acetal-containing hydrophobic tails. When formulated with DOPE, cholesterol and DMG-PEG2000, CA2d LNPs crossed the blood-brain barrier through caveolae- and γ-secretase-associated transcytosis and delivered mRNA to neurons, astrocytes, microglia and brain endothelial cells. Following intravenous administration of FLuc mRNA at 0.5 mg/kg in mice, CA2d produced 16.6-fold higher brain expression than MC3 and 8.6-fold higher expression than SM-102 at 6 hours. CA2d was further evaluated in repeated brain-cell transfection studies, a pilot rhesus macaque experiment and a tPA-modified TGF-β1 mRNA formulation for ischemic stroke. These results support CA2d as a promising preclinical research lipid for investigating non-viral CNS mRNA delivery; it has not been clinically validated.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →